Magnetic resonance monitoring of lesion evolution in multiple sclerosis

Therapeutic Advances in Neurological Disorders

Volumn 6, Issue 5, 2013, Pages 298-310

  Rovira, Alex ^a   Auger, Cristina ^a   Alonso, Juli ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

diffusion weighted imaging; lesion development; magnetic resonance imaging; magnetization transfer imaging; multiple sclerosis; proton magnetic resonance spectroscopy

Indexed keywords

CREATINE PHOSPHATE; GLUTAMINE; INOSITOL; LACTIC ACID; LIPID; N ACETYLASPARTIC ACID;

BRAIN DAMAGE; CONTRAST ENHANCEMENT; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; MACROMOLECULE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW;

EID: 84883318001     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285613484079     Document Type: Article

References (60)

1. Arnold D. de Stefano N. Narayanan S. Matthews P. (2000) Proton MR spectroscopy in multiple sclerosis. Neuroimaging Clin N Am 10: 789–798.
2. Arnold D. Matthews P. Francis G. O'Connor J. Antel J. (1992) Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 31: 235–241.
3. Barkhof F. (2002) The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 15: 239–245.
4. Barkhof F. Calabresi P. Miller D. Reingold S. (2009) Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 5: 256–266.
5. Budde M. Kim J. Liang H. Schmidt R. Russell J. Cross A. et al. (2007) Toward accurate diagnosis of white matter pathology using diffusion tensor imaging. Magn Reson Med 57: 688–695.
6. Castriota-Scanderbeg A. Fasano F. Hagberg G. Nocentini U. Filippi M. Caltagirone C. (2003) Coefficient D(av) is more sensitive than fractional anisotropy in monitoring progression of irreversible tissue damage in focal nonactive multiple sclerosis lesions. AJNR Am J Neuroradiol 24: 663–670.
7. Chen J. Collins D. Atkins H. Freedman M. Arnold D. for the Canadian MS / BMT Study Group (2008) Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 63: 254–262.
8. Confavreux C. Vukusic S. Moreau T. Adeleine P. (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343: 1430–1438.
9. Cotton F. Weiner H. Jolesz F. Guttmann C. (2003) MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 60: 640–646.
10. Davie C. Hawkins C. Barker G. Brennan A. Tofts P. Miller D. et al. (1994) Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 117: 49–58.
11. Davis M. Auh S. Riva M. Richert N. Frank J. McFarland H. et al. (2010) Ring and nodular multiple sclerosis lesions: a retrospective natural history study. Neurology 74: 851–856.
12. Deloire-Grassin M. Brochet B. Quesson B. Delalande C. Dousset V. Canioni P. et al. (2000) In vivo evaluation of remyelination in rat brain by magnetization transfer imaging. J Neurol Sci 178: 10–16.
13. de Stefano N. Matthews P. Antel J. Preul M. Francis G. Arnold D. (1995) Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 38: 901–909.
14. de Stefano N. Matthews P. Arnold D. (1995) Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 34: 721–727.
15. Dousset V. Grossman R. Ramer K. Schnall M. Young L. Gonzalez-Scarano F. et al. (1992) Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology 182: 483–491.
16. Eisele P. Szabo K. Griebe M. Rossmanith C. Förster A. Hennerici M. et al. (2012) Reduced diffusion in a subset of acute MS lesions: a serial multiparametric MRI study. AJNR Am J Neuroradiol 33: 1369–1373.
17. Fazekas F. Ropele S. Enzinger C. Seifert T. Strasser-Fuchs S. (2002) Quantitative magnetization transfer imaging of pre-lesional white-matter changes in multiple sclerosis. Mult Scler 8: 479–484.
18. Filippi M. (2000) Enhanced magnetic resonance imaging in multiple sclerosis. Mult Scler 6: 320–326.
19. Filippi M. Agosta F. (2007) Magnetization transfer MRI in multiple sclerosis. J Neuroimaging 17: 22S–26S.
20. Filippi M. Rocca M. Martino G. Horsfield M. Comi G. (1998) Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol 43: 809–814.
21. Fox R. Cronin T. Lin J. Wang X. Sakaie K. Ontaneda D. et al. (2011) Measuring myelin repair and axonal loss with diffusion tensor imaging. AJNR Am J Neuroradiol 32: 85–91.
22. Gaitán M. Shea C. Evangelou I. Stone R. Fenton K. Bielekova B. et al. (2011) Evolution of the blood–brain barrier in newly forming multiple sclerosis lesions. Ann Neurol 70: 22–29.
23. Giacomini P. Arnold D. (2008) Non-conventional MRI techniques for measuring neuroprotection, repair and plasticity in multiple sclerosis. Curr Opin Neurol 21: 272–277.
24. Graves D. Frohman T. Flores A. Hardeman P. Logan D. et al. (2012) Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord 5: 205–220.
25. Hattingen E. Magerkurth J. Pilatus U. Hübers A. Wahl M. Ziemann U. (2011) Combined (1) H and (31) P spectroscopy provides new insights into the pathobiochemistry of brain damage in multiple sclerosis. NMR Biomed 24: 536–546.
26. Horsfield M. Barker G. Barkhof F. Miller D. Thompson A. Filippi M. (2003) Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis. J Magn Reson Imaging 17: 389–397.
27. Kappos L. Weinshenker B. Pozzilli C. Thompson A. Dahlke F. Beckmann K. et al. (2004) European (EU-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board; North American (NA-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 63: 1779–1787.
28. Khan O. Shen Y. Bao F. Caon C. Tselis A. Latif Z. et al. (2008) Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-term H-MRS monitoring in multiple sclerosis. J Neuroimaging 18: 314–319.
29. Kutzelnigg A. Lucchinetti C. Stadelmann C. Brück W. Rauschka H. Bergmann M. et al. (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128: 2705–2712.
30. Lassmann H. (2008) The pathologic substrate of magnetic resonance alterations in multiple sclerosis. Neuroimaging Clin N Am 18: 563–576.
31. Lublin F. Reingold S. (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46: 907–911.
32. Mader I. Roser W. Kappos L. Hagberg G. Seelig J. Radue E. et al. (2000) Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. AJNR Am J Neuroradiol 21: 1220–1227.
33. Mader I. Seeger U. Weissert R. Klose U. Naegele T. Melms A. et al. (2001) Proton MR spectroscopy with metabolite-nulling reveals elevated macromolecules in acute multiple sclerosis. Brain 124: 953–961.
34. Meier D. Guttmann C. (2003) Time-series analysis of MRI intensity patterns in multiple sclerosis. Neuroimage 20: 1193–1209.
35. Meier D. Weiner H. Guttmann C. (2007 a) MR imaging intensity modeling of damage and repair in multiple sclerosis: relationship of short-term lesion recovery to progression and disability. AJNR Am J Neuroradiol 28: 1956–1963.
36. Meier D. Weiner H. Guttmann C. (2007 b) Time-series modeling of multiple sclerosis disease activity: a promising window on disease progression and repair potential? Neurotherapeutics 4: 485–498.
37. Miller D. Leary S. (2007) Primary-progressive multiple sclerosis. Lancet Neurol 6: 903–912.
38. Narayana P. Doyle T. Lai D. Wolinsky J. (1998) Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 43: 56–71.
39. Pagani E. Bammer R. Horsfield M. Rovaris M. Gass A. Ciccarelli O. et al. (2007) Diffusion MR imaging in multiple sclerosis: technical aspects and challenges. AJNR Am J Neuroradiol 28: 411–420.
40. Piani D. Frei K. Do K. Cuénod M. Fontana A. (1991) Murine brain macrophages induced NMDA receptor mediated neurotoxicity in vitro by secreting glutamate. Neurosci Lett 133: 159–162.
41. Pike G. de Stefano N. Narayanan S. Worsley K. Pelletier D. Francis G. et al. (2000) Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. Radiology 215: 824–883.
42. Rocca M. Cercignani M. Iannucci G. Comi G. Filippi M. (2000) Weekly diffusion-weighted imaging of normal-appearing white matter in MS. Neurology 55: 882–884.
43. Rovaris M. Gass A. Bammer R. Hickman S. Ciccarelli O. Miller D. et al. (2005) Diffusion MRI in multiple sclerosis. Neurology 65: 1526–1532
44. Rovaris M. Iannucci G. Falautano M. Possa F. Martinelli V. Comi G. et al. (2002) Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. J Neurol Sci 195: 103–109.
45. Rovira A. Pericot I. Alonso J. Rio J. Grivé E. Montalban X. (2002) Serial diffusion-weighted MR imaging and proton MR. AJNR Am J Neuroradiol 23: 989–994.
46. Sahraian M. Radue E. Haller S. Kappos L. (2010) Black holes in multiple sclerosis: definition, evolution, and clinical correlations. Acta Neurol Scand 122: 1–8.
47. Sajja B. Narayana P. Wolinsky J. Ahn C. for the PROMiSe Trial MRSI Group (2008) Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study. Mult Scler 14: 73–80.
48. Sajja B. Wolinsky J. Narayana P. (2009) Proton magnetic resonance spectroscopy in multiple sclerosis. Neuroimaging Clin N Am 19: 45–58.
49. Sarchielli P. Presciutti O. Tarducci R. Gobbi G. Alberti A. Pelliccioli G. et al. (1998) 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. J Neurol Neurosurg Psychiatry 64: 204–212.
50. Schmierer K. Scaravilli F. Altman D. Barker G. Miller D. (2004) Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 56: 407–415.
51. Schubert F. Seifert F. Elster C. Link A. Walzel M. Mientus S. et al. (2002) Serial 1H-MRS in relapsing-remitting multiple sclerosis: effects of interferon-beta therapy on absolute metabolite concentrations. MAGMA 14: 213–222.
52. Silver N. Lai M. Symms M. Barker G. McDonald W. Miller D. (1998) Serial magnetization transfer imaging to characterize the early evolution of new MS lesions. Neurology 51: 758–764.
53. Srinivasan R. Sailasuta N. Hurd R. Nelson S. Pelletier D. (2005) Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 128: 1016–1025.
54. Tartaglia M. Narayanan S. de Stefano N. Arnaoutelis R. Antel S. Francis S. et al. (2002) Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis. J Neurol 249: 1382–1390.
55. Tremlett H. Yinshan Z. Devonshire V. (2008) Natural history of secondary-progressive multiple sclerosis. Mult Scler 14: 314–324.
56. Urenjak J. Williams S. Gadian D. Noble M. (1993) Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 13: 981–989.
57. Werring D. Brassat D. Droogan A. Clark C. Symms M. Barker G. et al. (2000) The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain 123: 1667–1676.
58. Wolinsky J. Narayana P. O'Connor P. Coyle P. Ford C. Johnson K. et al. (2007) Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 61: 14–24.
59. Wuerfel J. Bellmann-Strobl J. Brunecker P. Aktas O. McFarland H. Villringer A. et al. (2004) Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain 127: 111–119.
60. Zaaraoui W. Rico A. Audoin B. Reuter F. Malikova I. Soulier E. et al. (2010) Unfolding the long-term pathophysiological processes following an acute inflammatory demyelinating lesion of multiple sclerosis. Magn Reson Imaging 28: 477–486.